Voyxact Preserves Kidney Function at Two Years in IgA Nephropathy, BTIG Says
BTIG analysts reviewed 24-month results from the VISIONARY trial of Voyxact (sibeprenlimab) in IgA nephropathy and found sustained improvement in estimated glomerular filtration rate (eGFR) versus placebo. The data met KDIGO benchmarks for slowing kidney decline. Otsuka has begun a rolling supplemental BLA and reported early commercial revenues and…